Randomized, double-blind, placebo-controlled clinical trial on the efficacy of 0.5% indomethacin eye drops in uveitic macular edema

Investigative Ophthalmology and Visual Science

Volumn 55, Issue 3, 2014, Pages 1463-1470

  Allegri, Pia ^a   Murialdo, Ugo ^a   Peri, Simona ^b   Carniglia, Rosanna ^b   Crivelli, Maria Grazia ^b   Compiano, Silvia ^a   Autuori, Silvia ^a   Mastromarino, Antonio ^a   Zurria, Monia ^c   Marrazzo, Giuseppina ^c  

^a Rapallo Hospital   (Italy)

^b Hospital of Sestri Levante   (Italy)

^c Reasearch and Development Alfa Intes Industria Terapeutica Splendore   (Italy)

Author keywords

0.5 indomethacin eye drops; Spectralis OCT; Uveitic macular edema

Indexed keywords

INDOM; INDOMETACIN; PLACEBO; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HUMAN; INTRAOCULAR PRESSURE; MALE; OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RETINA FOVEA; RETINA MACULA EDEMA; SLIT LAMP; UVEITIS; VISUAL ACUITY;

0.5% INDOMETHACIN EYE DROPS; SPECTRALIS OCT; UVEITIC MACULAR EDEMA;

AGED; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FUNDUS OCULI; HUMANS; INDOMETHACIN; MACULAR EDEMA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY;

EID: 84896383799     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.13-13202     Document Type: Article

References (75)

1. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm. 2003;11:29-38.
2. de Smet MD, Okada AA. Cystoid macular edema in uveitis. Dev Ophthalmol. 2010;47:136-147.
3. Rothova A. Inflammatory cystoid macular edema. Curr Opin Ophthalmol. 2007;18:487-492.
4. Lardenoye CW, van Kooij B, Rothova A. Impact of macular edema on visual acuity in uveitis. Ophthalmology. 2006;113: 1446-1449.
5. Bringmann A, Reichenbach A, Wiedermann P. Pathomechanisms of cystoids macular edema. Ophthalmic Res. 2004;36: 241-249.
6. Guex-Crosier Y. The pathogenesis and clinical presentation of macular edema in inflammatory diseases. Doc Ophthalmol. 1999;97:297-309.
7. Ursell PG, Spalton DJ, Whitcup SM, Nussenblatt RB. Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity. J Cataract Refract Surg. 1999;25:1492-1475.
8. Johnson MW. Etiology and treatment of macular edema. Am J Ophthalmol. 2009;147:11-21.
9. Saishin Y, Takahashi K, Melia M, Vinores SA, Campochiaro PA. Inhibition of protein kinase C decreases prostaglandin- induced breakdown of the blood-retinal barrier. J Cell Physiol. 2003;195:210-219.
10. Leal EC, Manivannan A, Hosoya K. Inducible nitric oxide synthase isoform is a key mediator of leukostasis and bloodretinal barrier breakdown in diabetic retinopathy. Invest Ophthalmol Vis Sci. 2007;48:5257-5265.
11. Tran TH, de Smet MD, Bodaghi B, Fardeau C, Cassoux N, Lehoang P. Uveitic macular oedema: correlation between optical coherence tomography patterns with visual acuity and fluorescein angiography. Br J Ophthalmol. 2008;92:922-927.
12. Hunter RS, Skondra D, Papaliodis G, Sobrin L. Role of OCT in the diagnosis and management of macular edema from uveitis. Semin Ophthalmol. 2012;27:236-241.
13. Iannetti L, Spinucci G, Abbouda A, de Geronimo D, Tortorella P, Accorinti M. Spectral-domain optical coherence tomography in uveitic macular edema: morphological features and prognostic factors. Ophthalmologica. 2012;228:13-18.
14. Gaynes BI, Fiscella R. Topical nonsteroidal anti-inflammatory drugs for ophthalmic use: a safety review. Drug Saf. 2002;25: 233-250.
15. Guex-Crosier Y. Non-steroidal anti-inflammatory drugs and ocular inflammation. Klin Mon Augenheilkd. 2001;218:305-308.
16. Warren KA, Bahrani H, Fox JE. Non-steroidal anti-inflammatory drugs in combination therapy for the treatment of chronic pseudophakic cystoid macular edema. Retina. 2010;30:260-266.
17. Nichols J, Snyder RW. Topical nonsteroidal anti-inflammatory agents in ophthalmology. Curr Opin Ophthalmol. 1998;9:40-44.
18. Waterbury LD, Silliman D, Jolas T. Comparison of cyclooxygenase inhibitory activity and ocular anti-inflammatory effects of ketorolac tromethamine and bromfenac sodium. Curr Med Res Opin. 2006;22:1133-1140.
19. Van Haeringen NJ, van Sorge AA, Carballosa Core-Bodelier VM. Constitutive cyclooxygenase-1 and induced cyclooxygenase-2 in isolated human iris inhibited by S({thorn}) flurbiprofen. J Ocul Pharmacol Ther. 2000;16:353-361.
20. Schilling H, Pauleikhoff D, Schrenk M, Wessing A. Therapy of cystoid diffuse macular edema after uveitis and cataract surgery with carbonic anhydrase inhibitor acetazolamide. Klin Monbl Augenheilkd. 1993;202:206-211.
21. Neri P, Mariotti C, Cimino L, Mercanti L, Giovannini A. Long term control of cystoid macular oedema in noninfectious uveitis with mycofenolate mofetil. Int Ophthalmol. 2009;29: 127-133.
22. Deuter CM, Kötter I, Günaydin I, Stübiger N, Doycheva DG, Zierhut M. Efficacy and tolerability of interferon alpha treatment in patients with chronic cystoid macular oedema due to non-infectious uveitis. Br J Ophthalmol. 2009;93:906-913.
23. Cho H, Madu A. Etiology and treatment of the inflammatory causes of cystoid macular edema. J Inflamm Res. 2009;2:37- 43.
24. Karim R, Sykakis E, Lightman S, Fraser-Bell S. Interventions for the treatment of uveitic macular edema: a systematic review and meta-analysis. Clin Ophthalmol. 2013;7:1109-1144.
25. Multicenter Uveitis Steroid Treatment Trial Research Group, Kempen JH, Altaweel MM, Holbrook JT, Jabs DA, Sugar EA. The multicenter uveitis steroid treatment trial: rationale, design, baseline characteristics. Am J Ophthalmol. 2010;149:550-561.
26. Becker M, Davis J. Vitrectomy in the treatment of uveitis. Am J Ophthalmol. 2005;140:1096-1105.
27. Gutfleisch M, Spital G, Mingels A, Pauleikhoff D, Lommatzsch A, Heiligenhaus A. Pars plana vitrectomy with IVTA effect on uveitic cystoid macular oedema and treatment limitations. Br J Ophthalmol. 2007;91:345-348.
28. Grover S, Murthy RK, Brar VS, Chalam KV. Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (spectralis). Am J Ophthalmol. 2009; 148:266-271.
29. Giani A, Cigada M, Choudhry N, et al. Reproducibility of retinal thickness measurements on normal and pathologic eyes by different optical coherence tomography instruments. Am J Ophthalmol. 2010;150:815-824.
30. Wolf-Schnurrbusch UE, Ceklic L, Brinkmann CK, et al. Macular thickness measurements in healthy eyes using six different optical coherence tomography instruments. Invest Ophthalmol Vis Sci. 2009;50:3432-3437.
31. Stewart R, Grosserode R, Cheetham JK, Rosenthal A. Efficacy and safety profile of ketorolac 0.5% ophthalmic solution in the prevention of surgically induced miosis during cataract surgery. Clin Ther. 1999;21:723-732.
32. Tinkelman DG, Rupp G, Kaufman H, Pugely J, Schulz N. Double masked, paired-comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol. 1993;38:133-140.
33. Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocular Pharmacol Ther. 1998;14:137-145.
34. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg. 2004;30:1653-1660.
35. O'Brien TP. Emerging guidelines for use of NSAID therapy to optimized cataract surgery patient care. Curr Med Res Opin. 2005;21:1131-1137.
36. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol. 2000;1:3-6.
37. Wilkinson-Berka JL, Alousis NS, Kelly DJ, Gilbert RE. COX-2 inhibition and retinal angiogenesis in a mouse model of retinopathy of prematurity. Invest Ophthalmol Vis Sci. 2003; 44:974-979.
38. Takahashi K, Saishin Y, Mori K, et al. Topical nepafenac inhibits ocular neovascularization. Invest Ophthalmol Vis Sci. 2003;44:409-415.
39. Singh R, Alpern L, Jaffe GJ, et al. Evaluation of nepafenac in prevention of macular edema following cataract surgery in patients with diabetic retinopathy. Clin Ophthalmol. 2012;6: 1259-1269.
40. Simone JN, Pendelton RA, Jenkins JE. Comparison of the efficacy and safety of ketorolac tromethamine 0.5% and prednisolone acetate 1% after cataract surgery. J Cataract Refract Surg. 1999;25:699-704.
41. Miyake K, Masuda K, Shirato S, et al. Comparison of diclofenac and fluorometholone in preventing cystoid macular edema after small incision cataract surgery: a multicenter prospective trial. Jpn J Ophthalmol. 2000;44:58-67.
42. Frucht-Pery J, Siganos CS, Solomon A, et al. Topical indomethacin solution versus dexamethasone solution for treatment of inflamed pterygium and pinguecula: a prospective randomized clinical study. Am J Ophthalmol. 1999;127:148-152.
43. Warren KA, Fox JE. Topical nepafenac as an alternative treatment for cystoid macular edema in steroid responsive patients. Retina. 2008;28:1427-1434.
44. Rossetti L, Bujtar E, Castoldi D, Torrassa C, Orzalesi N. Effectiveness of diclofenac eyedrops in reducing inflammation and the incidence of cystoid macular edema after cataract surgery. J Caract Refract Surg. 1996;2:794-799.
45. Warren KA, Bahrani H, Fox JE. NSAIDs in combination therapy for the treatment of chronic pseudophakic cystoids macular edema. Retina. 2010;30:260-266.
46. Solomon LD. Efficacy of topical flurbiprofen and indomethacin in preventing pseudophakic cystoid macular edema. Flurbiprofen- CME Study Group I. J Cataract Refract Surg. 1995;21: 73-81.
47. Weber M, Kodjian L, Kruse FE, Zagorski Z, Allaire CM. Efficacy and safety of indomethacin 0.1% eye drops compared with ketorolac 0.5% eye drops in the management of ocular inflammation after cataract surgery. Acta Ophthalmol. 2013; 91:e15-e21.
48. Raizman MB. NSAIDs crucial in preventing cystoid macular edema. Ocular Surg News. 2006. http://www.healio.com/ophthalmology/cataract-surgery/news/online/%7B29ac08d9-a235-4dc5-b9e9-b4b2af888149%7D/nsaids-crucial-in-preventing-cystoid-macularedema. Accessed May 15, 2006.
49. Sivaprasad S, Bunce C, Crosby N, Nwaobi R. Non-steroidal antiinflammatory agents for treating cystoid macular oedema following cataract surgery. Cochrane Database Syst Rev. 2012; 2:CD004239.
50. Yavas GF, Oztürk F, Küsbeci T. Preoperative topical indomethacin to prevent pseudophakic CME. J Cataract Refract Surg. 2007;33:804-807.
51. Halim MA, Mahmoud AA. Formulation of indomethacin eye drops via complexation with cyclodextrins. Curr Eye Res. 2011;36:208-216.
52. Bucolo C, Melilli B, Piazza C, Zurria M, Drago F. Ocular pharmacokinetics profile of different indomethacin topical formulations. J Ocul Pharmacol Ther. 2011;27:571-576.
53. Kaiser PK, Pineda R II. A study of topical nonsteroidal antiinflammatory drops and no pressure patching in the treatment of corneal abrasions. Ophthalmology. 1997;104:1353-1359.
54. Di Pascuale MA, Whitson JT, Mootha VV. Corneal melting after use of nepafenac in a patient with chronic cystoid macular edema after cataract surgery. Eye Contact Lens. 2008;34:129-130.
55. Isawi H, Dhaliwal DK. Corneal melting and perforation in Stevens Johnson syndrome following topical bromfenac use. J Cataract Refract Surg. 2007;33:1644-1646.
56. Asai T, Nakagami T, Mochizuki M, et al. Three cases of corneal melting after instillation of a new nonsteroidal anti-inflammatory drug. Cornea. 2006;25:224-227.
57. Yamaguchi M, Ueda K. Isowaki. et al. Mucoadhesive properties of chitosan-coated ophthalmic lipid emulsion containing indomethacin in tear fluid. Biol Pharm Bull. 2009;32:1266-1271.
58. Hariprasad SM, Akduman L, Clever JA, Ober M, Recchia FM, Mieler WF. Treatment of cystoid macular edema with the newgeneration NSAID nepafenac 0.1%. Clin Ophthalmol. 2009;3: 147-154.
59. Hariprasad SM, Callanan D, Gainey S, He YG, Warren K. Topical nepafenac 0.1% for treatment of chronic uveitic cystoid macular edema. Retin Cases Brief Rep. 2008;2:304-308.
60. Wolf EJ, Braunstein A, Shih C, Braunstein RE. Incidence of visual significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac. J Cataract Refract Surg. 2007;33:1546-1549.
61. Walters T, Raizman M, Ernest P, Gayton J, Lehmann R. In vivo pharmacokinetics and in vitro pharmacodynamics of nepafenac, amfenac, ketorolac, and bromfenac. J Cataract Refract Surg. 2007;33:1539-1545.
62. Endo N, Kato S, Haruyama K, Shoji M, Kitano S. Efficacy of bromfenac sodium ophthalmic solution in preventing cystoid macular oedema after cataract surgery in patients with diabetes. Acta Ophthalmol. 2010;88:896-900.
63. Miyanaga M, Miyai T, Nejima R, Maruyama Y, Miyata K, Kato S. Effect of bromfenac ophthalmic solution on ocular inflammation following cataract surgery. Acta Ophthalmol. 2009;87: 300-305.
64. Heier JS, Awh CC, Busbee BG, et al. Vitreous nonsteroidal antiinflammatory drug concentrations and prostaglandin E2 levels in vitrectomy patients treated with ketorolac 0.4%, bromfenac 0.09%, and nepafenac 0.1%. Retina. 2009;29:1310-1313.
65. Lindstrom R, Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr Med Res Opin. 2006;22:1237.
66. Kapin MA, Yanni JM, Brady MT, et al. Inflammation-mediated retinal edema in the rabbit is inhibited by topical nepafenac. Inflammation. 2003;27:281-291.
67. Jones J, Francis P. Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent. Expert Opin Pharmacother. 2009;10:2379-2385.
68. Radwan AE, Arcinue CA, Yang P, Artornsombudh P, Abu Al-Fadl EM, Foster CS. Bromfenac alone or with single intravitreal injection of bevacizumab or triamcinolone acetonide for treatment of uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2013;251:1801-1806.
69. Cable M. Comparison of bromfenac 0.09% QD to nepafenac 0.1% TID after cataract surgery: pilot evaluation of visual acuity, macular volume, and retinal thickness at a single site. Clin Ophthalmol. 2012;6:997-1004.
70. Flach AJ. Topical nonsteroidal anti-inflammatory drugs in ophthalmology. Int Ophthalmol Clin. 2002;42:1-11.
71. Kim SJ, Doherty TJ, Cherney EF. Intravitreal ketorolac for chronic uveitis and macular edema: a pilot study. Arch Ophthalmol. 2012;130:742-748.
72. Wright PL, Wilkinson CP, Balyeat HD, Popham J, Reinke M. Angiographic cystoid macular edema after posterior chamber lens implantation. Arch Ophthalmol. 1988;106:740-744.
73. Roesel M, Henschel A, Heinz C, Dietzel M, Spital G, Heiligenhaus A. Fundus autofluorescence and spectral domain optical coherence tomography in uveitic macular edema. Graefes Arch Clin Exp Ophthalmol. 2009;247:1685-1689.
74. Ossewaarde-van Norel J, Camfferman LP, Rothova A. Discrepancies between fluorescein angiography and optical coherence tomography in macular edema in uveitis. Am J Ophthalmol. 2012;154:233-239.
75. Markomichelakis NN, Halkiadakis I, Pantelia E, et al. Patterns of macular edema in patients with uveitis: qualitative and quantitative assessment using optical coherence tomography. Ophthalmology. 2004;111:946-953.